bioRxiv · 10.1101/2025.10.25.684565
Antibodies blocking PlGF or VEGF interactions with the NRP1 receptormediate anti-proliferative effects
Abstract
Antibodies blocking the function of vascular endothelial growth factor A (VEGFA) remain a promising therapeutic strategy, especially when combined with check-point inhibitors, but their efficacy is limited by tumor resistance. This can occur via multiple mechanisms, including upregulation of placental growth factor 2 (PlGF-2), an alternative ligand for VEGF receptor 1 (VEGFR1) and neuropilin receptor 1 (NRP1). Activity of both growth factors is mediated by interactions with multiple receptors and extra-cellular matrix components, which complicates efforts to understand their contributions to cancer progression. To complement existing antibodies, we discovered those blocking interactions between PlGF-2 or VEGFA and their shared NRP1 receptor in the presence of heparin. Limiting angiogenesis to promote vascular normalization is one mechanism of anti-VEGF protection; here, anti-VEGFA antibodies blocking interactions with VEGFR1 and NRP1 reduced HUVEC tube formation in a physiological angiogenesis model. By contrast, antibodies binding PlGF-2 or VEGFA to block NRP1 significantly reduced proliferation of Caki-I kidney carcinoma cells in vitro, indicating this receptor mediates additional effects. Interestingly, one antibody exhibited dual-reactive binding to VEGFA and PlGF-2, suggesting a novel therapeutic strategy to prevent PlGF-driven VEGF-resistance. Overall, these antibodies define new mechanisms to disrupt PlGF activity and support a role for NRP1 in cell proliferation. Key ResultsO_LINew antibodies binding VEGFA or PlGF selectively block NRP1-receptor interactions. C_LIO_LIAntibody blockade of VEGFA binding to NRP1 reduced HUVEC angiogenesis. C_LIO_LIBlocking growth factor interactions with NRP1 reduced Caki-I renal carcinoma proliferation. C_LIO_LIIdentified an antibody with dual-reactive binding to VEGFA and PlGF. C_LI
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Blackman, S. A., Qerqez, A. N., Lee, A. G., Johnson, N. V., Owens, J. M., Lai, G. S., Aldrich, E. C., Sprenger, K. G., Lee, J., Verrier, S., Stoddart, M. J., Nguyen, A. W., Maynard, J. A.. 2025-10-26. Antibodies blocking PlGF or VEGF interactions with the NRP1 receptormediate anti-proliferative effects. https://doi.org/10.1101/2025.10.25.684565
Cite the original work for its findings. Save a collection to share your selection of sources.